810 related articles for article (PubMed ID: 8263772)
1. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
2. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
4. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
5. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
6. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
7. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model.
Lawler CP; Gilmore JH; Watts VJ; Walker QD; Southerland SB; Cook LL; Mathis CA; Mailman RB
Synapse; 1995 Dec; 21(4):299-311. PubMed ID: 8869160
[TBL] [Abstract][Full Text] [Related]
8. 6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
Rangel-Barajas C; Silva I; García-Ramírez M; Sánchez-Lemus E; Floran L; Aceves J; Erlij D; Florán B
Neuropharmacology; 2008 Oct; 55(5):704-11. PubMed ID: 18588904
[TBL] [Abstract][Full Text] [Related]
9. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
Jackson D; Abercrombie ED; Zigmond MJ
J Pharmacol Exp Ther; 1993 Nov; 267(2):912-8. PubMed ID: 8246167
[TBL] [Abstract][Full Text] [Related]
10. Dopamine receptor changes in response to prolonged treatment with L-dopa.
Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
12. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
14. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
15. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat.
Simson PE; Johnson KB; Jurevics HA; Criswell HE; Napier TC; Duncan GE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Dec; 263(3):1454-63. PubMed ID: 1361576
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation.
Thomas KL; Rose S; Jenner P; Marsden CD
Biochem Pharmacol; 1992 Jul; 44(1):73-82. PubMed ID: 1321630
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Calabresi P; Mercuri NB; Sancesario G; Bernardi G
Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Glavan G; Zivin M
Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
[TBL] [Abstract][Full Text] [Related]
19. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
Meissner W; Ravenscroft P; Reese R; Harnack D; Morgenstern R; Kupsch A; Klitgaard H; Bioulac B; Gross CE; Bezard E; Boraud T
Neurobiol Dis; 2006 Jun; 22(3):586-98. PubMed ID: 16531050
[TBL] [Abstract][Full Text] [Related]
20. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
Brannan T; Knott P; Kaufmann H; Yahr M
Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
